{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:09:48Z","timestamp":1781762988214,"version":"3.54.5"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The utility of measuring thiopurine metabolites (TM) to individualize therapy in autoimmune hepatitis (AIH) has not been defined, and the evidence regarding its use in clinical practice is heterogeneous. This systematic review and meta-analysis aimed to compare the mean concentration of TM between patients in biochemical remission and those not in remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic literature search was conducted using PubMed, Scopus, the Cochrane Library, and Google Scholar for keywords related to TM and AIH. Two reviewers independently searched and selected studies comparing the levels of 6-methyl mercaptopurine (6-MMP) and 6-thioguanine nucleotide (6-TGN) and their ratio in cases of AIH in remission and otherwise. Meta-analysis was performed by calculating the weighted mean difference using the inverse variance heterogeneity model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 1066 records were identified through systematic search; of which, 7 (n = 3 pediatric, n = 4 adults) were considered for inclusion, and 442 TM measurements (n = 128 in children) were analyzed. Mean 6-TGN levels were significantly higher among patients in remission than in those who were not, with a pooled weighted mean difference (WMD) of 15.67 [95% confidence interval (CI), 6.68\u201324.66] pmol\/8 \u00d7 10<jats:sup>8<\/jats:sup> red blood cells (RBC). The difference was higher in the pediatric age group (WMD, 56.11; 95% CI, 13.60\u201398.62) than in adults (WMD, 13.77; 95% CI, 4.58\u201322.97). There was no significant difference in the 6-MMP levels (WMD, \u2212431.7; 95% CI, \u22121237.4 to 373.9 pmol\/8 \u00d7 10<jats:sup>8<\/jats:sup> RBC; I<jats:sup>2<\/jats:sup> = 82%; n = 3 studies) or 6-MMP\/6-TGN ratio among the patients who were in biochemical remission and those who were not (WMD, \u22120.97; 95% CI, \u22125.77 to 3.84; I<jats:sup>2<\/jats:sup> = 82%; n = 3 studies).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This meta-analysis suggests a link between 6-TGN levels and biochemical remission in AIH. Further high-quality studies are required to determine the therapeutic cutoff of 6-TGN.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000848","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T13:01:54Z","timestamp":1608555714000},"page":"609-616","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Systematic Review and Meta-Analysis of Thiopurine Metabolite Levels and Biochemical Remission in Autoimmune Hepatitis"],"prefix":"10.1097","volume":"43","author":[{"given":"Rishi","family":"Bolia","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Community and Family Medicine, All India Institute of Medical Sciences, Jodhpur; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MPG.0000000000002146","article-title":"Lower 6-MMP\/6-TG ratio may be a therapeutic target in pediatric autoimmune hepatitis","volume":"67","author":"Bolia","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14740338.7.3.319","article-title":"Safety issues in the management of autoimmune hepatitis","volume":"7","author":"Czaja","year":"2008","journal-title":"Expert Opin Drug Saf."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.21787","article-title":"Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease","volume":"46","author":"Montano-Loza","year":"2007","journal-title":"Hepatology."},{"key":"R5-20250603","first-page":"391","article-title":"Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report","volume":"35","author":"Rumbo","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jhep.2009.10.004","article-title":"Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis","volume":"52","author":"Hindorf","year":"2010","journal-title":"J Hepatol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1155\/2011\/137476","article-title":"Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in AK native and other non-Caucasian people","volume":"25","author":"Ferucci","year":"2011","journal-title":"Can J Gastroenterol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2006.05.011","article-title":"Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis","volume":"45","author":"Heneghan","year":"2006","journal-title":"J Hepatol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.25760","article-title":"Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis","volume":"56","author":"Dhaliwal","year":"2012","journal-title":"Hepatology."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MPG.0000000000001563","article-title":"Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites","volume":"65","author":"Sheiko","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/FTD.0b013e3181dbd712","article-title":"Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis","volume":"32","author":"Nguyen","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R12-20250603","first-page":"1","article-title":"Utility of monitoring azathioprine metabolites in the management of children with autoimmune hepatitis","volume":"2","author":"Jannone","year":"2016","journal-title":"J Hepatol Gastroint Dis."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/01.MIB.0000439068.71126.00","article-title":"Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis","volume":"20","author":"Moreau","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00007691-200206000-00005","article-title":"Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate","volume":"24","author":"Pettersson","year":"2002","journal-title":"Ther Drug Monit."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/gut.2003.032896","article-title":"Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease","volume":"53","author":"Wright","year":"2004","journal-title":"Gut."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.49.5.665","article-title":"Measurement of thiopurine methyl transferase activity and azathioprine metabolites in patients with inflammatory bowel disease","volume":"49","author":"Lowry","year":"2001","journal-title":"Gut."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/00042737-200412000-00028","article-title":"Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis","volume":"16","author":"Wusk","year":"2004","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jceh.2017.01.115","article-title":"Role of allopurinol in optimizing thiopurine therapy in patients with autoimmune hepatitis: a review","volume":"7","author":"Deswal","year":"2017","journal-title":"J Clin Exp Hepatol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:12:24Z","timestamp":1748970744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000848","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"2020-08-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}